Atezolizumab Plus Modified Docetaxel, Cisplatin, and Fluorouracil as a First-Line Treatment for Advanced Anal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study
Lancet Oncol 2024 Apr 01;25(4)518-528, S Kim, F Ghiringhelli, C de la Fouchardière, L Evesque, D Smith, N Badet, E Samalin, D Lopez-Trabada Ataz, A Parzy, J Desramé, N Baba Hamed, B Buecher, D Tougeron, O Bouché, L Dahan, B Chibaudel, F El Hajbi, L Mineur, O Dubreuil, M Ben Abdelghani, S Pecout, F Bibeau, M Herfs, ML Garcia, A Meurisse, D Vernerey, J Taïeb, C BorgFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.